Coherus Biosciences Stock Alpha and Beta Analysis
| CHRS Stock | USD 0.92 0.03 3.37% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Coherus BioSciences. It also helps investors analyze the systematic and unsystematic risks associated with investing in Coherus BioSciences over a specified time horizon. Remember, high Coherus BioSciences' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Coherus BioSciences' market risk premium analysis include:
Beta 0.67 | Alpha (0.56) | Risk 5.25 | Sharpe Ratio (0.17) | Expected Return (0.88) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Coherus |
Coherus BioSciences Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Coherus BioSciences market risk premium is the additional return an investor will receive from holding Coherus BioSciences long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Coherus BioSciences. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Coherus BioSciences' performance over market.| α | -0.56 | β | 0.67 |
Coherus BioSciences expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Coherus BioSciences' Buy-and-hold return. Our buy-and-hold chart shows how Coherus BioSciences performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Coherus BioSciences Market Price Analysis
Market price analysis indicators help investors to evaluate how Coherus BioSciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Coherus BioSciences shares will generate the highest return on investment. By understating and applying Coherus BioSciences stock market price indicators, traders can identify Coherus BioSciences position entry and exit signals to maximize returns.
Coherus BioSciences Return and Market Media
The median price of Coherus BioSciences for the period between Sun, Dec 15, 2024 and Sat, Mar 15, 2025 is 1.28 with a coefficient of variation of 17.22. The daily time series for the period is distributed with a sample standard deviation of 0.22, arithmetic mean of 1.31, and mean deviation of 0.2. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 2073 shares by Paul Reider of Coherus BioSciences at 1.61 subject to Rule 16b-3 | 12/13/2024 |
2 | Disposition of 2277 shares by Paul Reider of Coherus BioSciences at 1.66 subject to Rule 16b-3 | 01/03/2025 |
3 | Disposition of 1711 shares by Bryan Mcmichael of Coherus BioSciences at 1.57 subject to Rule 16b-3 | 01/07/2025 |
4 | Acquisition by Dennis Lanfear of 575000 shares of Coherus BioSciences at 1.47 subject to Rule 16b-3 | 01/10/2025 |
5 | Coherus Biosciences Announces UDENYCA Divestiture and Revenue Outlook - TipRanks | 01/13/2025 |
6 | Disposition of 11810 shares by Dennis Lanfear of Coherus BioSciences at 1. subject to Rule 16b-3 | 01/17/2025 |
7 | Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with ... | 01/22/2025 |
8 | Coherus BioSciences Stock Crosses Above 200-Day Moving Average - Time to Sell - MarketBeat | 02/03/2025 |
9 | Rubric Capital Management LP Reduces Stake in Coherus BioSciences Inc | 02/14/2025 |
10 | With 59 percent institutional ownership, Coherus BioSciences, Inc. is a favorite amongst the big guns | 02/27/2025 |
11 | Acquisition by Paul Reider of 160000 shares of Coherus BioSciences at 3.14 subject to Rule 16b-3 | 02/28/2025 |
12 | Fortrea Holdings Inc. Q4 Earnings and Revenues Miss Estimates | 03/03/2025 |
13 | What To Expect From Coherus BioSciences Inc Q4 2024 Earnings | 03/07/2025 |
14 | Acquisition by Stolper Mark of 112000 shares of Coherus BioSciences at 1.76 subject to Rule 16b-3 | 03/10/2025 |
15 | Research Analysts Updated EPS Estimates for March 11th | 03/11/2025 |
16 | Coherus BioSciences Full Year 2024 Earnings Beats Expectations | 03/12/2025 |
About Coherus BioSciences Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Coherus or other stocks. Alpha measures the amount that position in Coherus BioSciences has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 (projected) | Current Ratio | 7.65 | 1.43 | 1.29 | Intangibles To Total Assets | 0.0123 | 0.11 | 0.1 |
Coherus BioSciences Upcoming Company Events
As portrayed in its financial statements, the presentation of Coherus BioSciences' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Coherus BioSciences' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Coherus BioSciences' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Coherus BioSciences. Please utilize our Beneish M Score to check the likelihood of Coherus BioSciences' management manipulating its earnings.
| 4th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Coherus BioSciences
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Coherus Stock Analysis
When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.